西米普利单抗治疗复发性宫颈癌:III期EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9试验总生存最终分析
该III期随机试验最终分析显示,在一线含铂化疗后进展的复发性宫颈癌患者中,西米普利单抗组(n=304)中位总生存为11.7个月,化疗组(n=304)为8.5个月(HR 0.67,95%CI 0.56-0.80,p<.00001),无论PD-L1表达状态均见生存获益,安全性特征与已发表数据一致。
要点
- 西米普利单抗较化疗显著延长复发性宫颈癌患者总生存:中位11.7 vs 8.5个月,HR 0.67。
- PD-L1阳性与阴性人群均观察到总生存获益。
- 安全性特征与已发表数据一致,两组不良事件发生率相似。
核心结论
- 最终分析证实,西米普利单抗在一线铂类治疗进展后的复发性宫颈癌中较化疗维持生存获益,无论PD-L1表达状态如何。
研究设计与样本
- III期随机研究EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9,西米普利单抗组n=304,化疗组n=304,每3周给药,主要终点为总生存,患者入组不考虑PD-L1状态。
主要发现
- 中位随访47.3个月(数据截止2023年4月20日),西米普利单抗组中位总生存11.7个月 vs 化疗组8.5个月(HR 0.67,95%CI 0.56-0.80,p<.00001)。
- PD-L1阳性与阴性人群均观察到总生存获益。
- 西米普利单抗组中PD-L1<1%患者(n=92)体能状态较差者比例高于化疗组(61.4% vs 47.9%)。
- 安全性特征与已发表数据一致,西米普利单抗组与化疗组不良事件发生率相似。
临床怎么用
- 这些结果支持西米普利单抗用于复发性宫颈癌的二线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Cemiplimab has demonstrated significantly longer survival than physician's choice of chemotherapy in patients with recurrent cervical cancer after first-line platinum-containing chemotherapy. We report the final survival analysis from the phase III randomized study (EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9). METHODS: Cemiplimab (n = 304) or chemotherapy (n = 304) were administered every 3 weeks. The primary endpoint was overall survival (OS). Patients were included regardless of programmed cell death-ligand 1 (PD-L1) status. RESULTS: At a median follow-up of 47.3 months (data cut-off: April 20, 2023), median OS was 11.7 versus 8.5 months for patients treated with cemiplimab and chemotherapy, respectively (hazard ratio 0.67, 95 % confidence interval 0.56-0.80, p < .00001). OS benefit was seen in PD-L1 positive and negative populations, even though more patients with PD-L1 < 1 % (n = 92), had poor performance status in the cemiplimab arm than the chemotherapy arm (61.4 % vs 47.9 %). CONCLUSION: This final analysis confirms that cemiplimab maintains survival benefit compared with chemotherapy in recurrent cervical cancer after progression on first-line platinum therapy, regardless of PD-L1 expression. The safety profile was consistent with published data; incidences of adverse events were similar between cemiplimab and chemotherapy groups. These results support the use of second-line cemiplimab for patients with recurrent cervical cancer.
引用
- Oaknin A, Monk BJ, de Melo AC, et al. Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial. Eur J Cancer. 2025. PMID: 39798514. doi:10.1016/j.ejca.2024.115146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。